Insulet’s (PODD) “Buy” Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Insulet (NASDAQ:PODD) in a research note released on Thursday morning,Benzinga reports. The firm currently has a $370.00 price target on the medical instruments supplier’s stock.

Other equities analysts also recently issued research reports about the stock. Royal Bank Of Canada increased their price target on shares of Insulet from $365.00 to $370.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Raymond James Financial lifted their price objective on Insulet from $360.00 to $366.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Jefferies Financial Group increased their price target on Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Canaccord Genuity Group boosted their target price on shares of Insulet from $399.00 to $428.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, UBS Group upped their price target on Insulet from $320.00 to $355.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $374.10.

Insulet Stock Up 0.0%

Insulet stock opened at $332.70 on Thursday. The stock’s fifty day moving average is $323.58 and its two-hundred day moving average is $312.46. The stock has a market cap of $23.40 billion, a PE ratio of 101.12, a P/E/G ratio of 2.64 and a beta of 1.39. Insulet has a 1-year low of $230.05 and a 1-year high of $353.50. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. The firm had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business’s revenue was up 29.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, sell-side analysts expect that Insulet will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is owned by company insiders.

Institutional Investors Weigh In On Insulet

Several hedge funds have recently made changes to their positions in PODD. Cerity Partners LLC raised its stake in Insulet by 28.7% during the 1st quarter. Cerity Partners LLC now owns 10,232 shares of the medical instruments supplier’s stock valued at $2,687,000 after purchasing an additional 2,284 shares during the period. CWM LLC boosted its position in Insulet by 1.6% during the 1st quarter. CWM LLC now owns 4,034 shares of the medical instruments supplier’s stock worth $1,059,000 after acquiring an additional 64 shares during the period. Larson Financial Group LLC increased its holdings in shares of Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 81 shares during the period. Forum Financial Management LP purchased a new stake in shares of Insulet in the first quarter worth approximately $300,000. Finally, Jennison Associates LLC grew its position in Insulet by 52.7% during the first quarter. Jennison Associates LLC now owns 241,717 shares of the medical instruments supplier’s stock valued at $63,477,000 after purchasing an additional 83,375 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.